Oxygen Biotherapeutics now has a clinical development pipeline which includes seven indications for Oxycyte(TM) emulsion. Oxycyte is the Company’s perfluorocarbon (PFC) therapeutic oxygen carrier. The new Oxycyte pipeline includes: Traumatic Brain Injury, Carbon Monoxide Poisoning, Surgical Iatrogenic Air Embolism, Spinal Cord Injury, Organ Preservation, Decompression Sickness, and Sickle Cell Crisis.

The company has also reported that its topical pipeline includes six additional indications in development for the Oxycyte Gel. The first use of the Dermacyte Gel is for a cosmetic line that is now available for pre-orders via the BuyDermacyte.com website, with product shipment expected in about four weeks. Other uses include treatment for Wounds, Burns, Acne, Rosacea, Cell Treatment after Radiation Therapy, and Erectile Dysfunction. Oxygen Biotherapeudics is also working on two additional uses for Oxycyte Compounds, including a ventilation device called VitaVent and a Deep Immersion Fluorocarbon Treatment for severe burns.

Oxygen Biotherapeutics CEO Chris Stern commented on the

Solei Systems Incorporated is an industry leader in the field of tanning and LED products. As of May 2, 2008 the company began trading on the Pink Sheets exchange, and CEO Paul Spivak anticipates that, within the next few months, the company will transition onto a senior exchange. The company consists of three divisions: Intelligent Tanning Systems (ITS), Light Therapy Systems (LTS) and BioScience Systems. All three of these divisions manufacture their own equipment in-house, which greatly reduces costs and increases efficiency.

The Intelligent Tanning Systems division is focused on sunless tanning machines and equipment to meet the needs of today’s marketplace. The tanning machines and equipment offered through ITS are ultra-violet (UV) free and offer an affordable option for both retail and residential customers. ITS has also developed a patent pending, state-of-the-art LED tanning technology that is the only one of its kind, and has